According to Renaissance Capital, 215 IPOs have priced in the United States so far this year, up 36% from a year ago. Total proceeds raised come to $70.6 billion, up about 109% from 2013. In the month of August, IPO proceeds totaled just $0.9 billion, the lowest monthly total so far in 2014. September’s total came to $28.5 billion, of which about $22 billion is attributed to the IPO of Alibaba Group Holding Ltd (NYSE: BABA). Last week’s IPOs put $2 billion on the October total, so the new month is off to a good start. The 2013 IPO total came in at $54.9 billion, the highest total in the past 10 years, and that has already been surpassed with more than three months left in 2014.
Eyegate Pharmaceuticals Inc., a clinical-state specialty biopharmaceutical firm developing treatments for eye diseases, has postponed its IPO. The company planned to offer 1.9 million shares in a price range of $12 to $14 to raise $25 million at a market cap of around $92 million.
Viking Therapeutics Inc., which has been held over for another week, is a clinical-stage biopharmaceutical company based in California and focused on developing therapies for metabolic and endocrine disorders. The company plans to offer 5 million shares in a price range of $10 to $12, raising $55 million at a market cap of about $167 million. The IPO is listed as day-to-day. Shares will trade on the Nasdaq under the ticker symbol VKTX.
The following are this week’s new IPOs:
HubSpot Inc., maker of a cloud-based software platform for inbound sales and marketing calls, plans to offer 5 million shares in an expected price range of $19 to $20 to raise $100 million at a market cap of about $607 million. Morgan Stanley, J.P. Morgan and UBS Investment Bank are joint managers of the offering, which is set to price on Wednesday and begin trading Thursday on the New York Stock Exchange (NYSE) under the ticker symbol HUBS.